D000071877D08.811.913.696.620.682.700.143971730.907865Checkpoint Kinase 1Faculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentDivisionvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonExperimental Radiation OncologyInvestigational Cancer TherapeuticsThoracic Head & Neck Medical OncologyMD AndersonLAUREN AVERETTBYERSLAUREN AVERETT BYERS8714BYERS, LAUREN AVERETTAssistant ProfessorHELENPIWNICA-WORMSHELEN PIWNICA-WORMS9896PIWNICA-WORMS, HELENProfessorDAVID SANGHYUNHONGDAVID SANGHYUN HONG9016HONG, DAVID SANGHYUNAssociate Professor74Professor10Assistant Professor29Clinical Associate Professor14Associate Professortrue1ProfessorProfessor29643063Hong DS, Moore K, Patel M, Grant SC, Burris HA, William WN, Jones S, Meric-Bernstam F, Infante J, Golden L, Zhang W, Martinez R, Wijayawardana S, Beckmann R, Lin AB, Eng C, Bendell JClinical cancer research : an official journal of the American Association for Cancer ResearchEvaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma. Clin Cancer Res. 2018 07 15; 24(14):3263-3272.Clin Cancer Res2018-04-11T00:00:002018Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma.Department of MedicineDepartment of Obstetrics & GynecologyMedicine-Hematology & OncologyObstetrics and GynecologyBaylor College of MedicineWEEI-CHINLINWEEI-CHIN LIN0.000000000000000.000000000000001687LIN, WEEI-CHINProfessorMEREDITHMORGANMEREDITH MORGAN29.73088400000000-95.388780000000002448MORGAN, MEREDITHClinical Associate Professor2.086550.013165997research area of0.8583290.0396801114subject area for32357935Yu X, Li W, Liu H, Deng Q, Wang X, Hu H, Xu-Monette ZY, Xiong W, Lu Z, Young KH, Wang W, Li YJournal of hematology & oncologyUbiquitination of the DNA-damage checkpoint kinase CHK1 by TRAF4 is required for CHK1 activation. J Hematol Oncol. 2020 05 01; 13(1):40.J Hematol Oncol2020-05-01T00:00:002020Ubiquitination of the DNA-damage checkpoint kinase CHK1 by TRAF4 is required for CHK1 activation.29895190Parsels LA, Parsels JD, Tanska DM, Maybaum J, Lawrence TS, Morgan MACell cycle (Georgetown, Tex.)The contribution of DNA replication stress marked by high-intensity, pan-nuclear ?H2AX staining to chemosensitization by CHK1 and WEE1 inhibitors. Cell Cycle. 2018; 17(9):1076-1086.Cell Cycle2018-07-18T00:00:002018The contribution of DNA replication stress marked by high-intensity, pan-nuclear ?H2AX staining to chemosensitization by CHK1 and WEE1 inhibitors.33556369Liu K, Graves JD, Lin FT, Lin WCThe Journal of biological chemistryOverexpression of TopBP1, a canonical ATR/Chk1 activator, paradoxically hinders ATR/Chk1 activation in cancer. J Biol Chem. 2021 Jan-Jun; 296:100382.J Biol Chem2021-02-05T00:00:002021Overexpression of TopBP1, a canonical ATR/Chk1 activator, paradoxically hinders ATR/Chk1 activation in cancer.35021084Qin T, Mullan B, Ravindran R, Messinger D, Siada R, Cummings JR, Harris M, Muruganand A, Pyaram K, Miklja Z, Reiber M, Garcia T, Tran D, Danussi C, Brosnan-Cashman J, Pratt D, Zhao X, Rehemtulla A, Sartor MA, Venneti S, Meeker AK, Huse JT, Morgan MA, Lowenstein PR, Castro MG, Yadav VN, Koschmann CCell reportsATRX loss in glioma results in dysregulation of cell-cycle phase transition and ATM inhibitor radio-sensitization. Cell Rep. 2022 01 11; 38(2):110216.Cell Rep2022-01-11T00:00:002022ATRX loss in glioma results in dysregulation of cell-cycle phase transition and ATM inhibitor radio-sensitization.true1Clinical Associate ProfessorClinical Associate Professortrue1Associate ProfessorAssociate Professortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessor